Showing 1 - 7 results of 7 for search 'T. Richard Nichols', query time: 0.03s Refine Results
  1. 1
    Editorial: Comparative neuromechanical circuits of the sensorimotor system

    Editorial: Comparative neuromechanical circuits of the sensorimotor system by T. Richard Nichols, Monica A. Daley

    Published 2022-07-01
    Get full text
    Article
  2. 2
    Immunological correlates of protection afforded by PHV02 live, attenuated recombinant vesicular stomatitis virus vector vaccine against Nipah virus disease

    Immunological correlates of protection afforded by PHV02 live, attenuated recombinant vesicular stomatitis virus vector vaccine against Nipah virus disease by Thomas P. Monath, Thomas P. Monath, Richard Nichols, Friederike Feldmann, Amanda Griffin, Elaine Haddock, Julie Callison, Kimberly Meade-White, Atsushi Okumura, Jamie Lovaglio, Patrick W. Hanley, Chad S. Clancy, Carl Shaia, Wasima Rida, Joan Fusco

    Published 2023-09-01
    Get full text
    Article
  3. 3
    A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18-40 Year Old Subjects with Diagnosed Atopic Dermatitis.

    A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18-40 Year Old Subjects with Diagnosed Atopic Derma... by Richard N Greenberg, Maria Yadira Hurley, Dinh V Dinh, Serena Mraz, Javier Gomez Vera, Dorothea von Bredow, Alfred von Krempelhuber, Siegfried Roesch, Garth Virgin, Nathaly Arndtz-Wiedemann, Thomas Peter Meyer, Darja Schmidt, Richard Nichols, Philip Young, Paul Chaplin

    Published 2015-01-01
    Get full text
    Article
  4. 4
    rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessment

    rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/be... by Thomas P. Monath, Patricia E. Fast, Kayvon Modjarrad, David K. Clarke, Brian K. Martin, Joan Fusco, Richard Nichols, D. Gray Heppner, Jakub K. Simon, Sheri Dubey, Sean P. Troth, Jayanthi Wolf, Vidisha Singh, Beth-Ann Coller, James S. Robertson

    Published 2019-04-01
    Get full text
    Article
  5. 5
    Correction: A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18-40 Year Old Subjects with Diagnosed Atopic Dermatitis.

    Correction: A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18-40 Year Old Subjects with Diagnosed... by Richard N Greenberg, Maria Yadira Hurley, Dinh V Dinh, Serena Mraz, Javier Gomez Vera, Dorothea von Bredow, Alfred von Krempelhuber, Siegfried Roesch, Garth Virgin, Nathaly Arndtz-Wiedemann, Thomas Peter Meyer, Darja Schmidt, Richard Nichols, Philip Young, Paul Chaplin

    Published 2015-01-01
    Get full text
    Article
  6. 6
    A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old Subjects.

    A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old S... by Richard N Greenberg, Christine M Hay, Jack T Stapleton, Thomas C Marbury, Eva Wagner, Eva Kreitmeir, Siegfried Röesch, Alfred von Krempelhuber, Philip Young, Richard Nichols, Thomas P Meyer, Darja Schmidt, Josef Weigl, Garth Virgin, Nathaly Arndtz-Wiedemann, Paul Chaplin

    Published 2016-01-01
    Get full text
    Article
  7. 7
    Recombinant vesicular stomatitis vaccine against Nipah virus has a favorable safety profile: Model for assessment of live vaccines with neurotropic potential.

    Recombinant vesicular stomatitis vaccine against Nipah virus has a favorable safety profile: Model for assessment of live vaccines with neurotropic potential. by Thomas P Monath, Richard Nichols, Lynda Tussey, Kelly Scappaticci, Thaddeus G Pullano, Mary D Whiteman, Nikos Vasilakis, Shannan L Rossi, Rafael Kroon Campos, Sasha R Azar, Heidi M Spratt, Brent L Seaton, W Tad Archambault, Yanina V Costecalde, Evan H Moore, Roger J Hawks, Joan Fusco

    Published 2022-06-01
    Get full text
    Article

Search Tools: